Navigation Links
Champions Oncology Reports Full Year 2011 Financial Results
Date:7/15/2011

BALTIMORE, July 15, 2011 /PRNewswire/ -- Champions Oncology, Inc., formerly Champions Biotechnology, Inc., (OTC: CSBR):

Highlights:

  • Company completes $9.4 million financing during 2011
  • Revenue growth of 41% to $6.9 million
  • Net loss of $3.8 million; excluding stock based compensation a net loss of $0.7 million*
  • Net loss of ($0.10) per share; net loss excluding stock-based compensation of ($0.02) per share*
  • Cash of $10.5 million at year end

  • Annual 2011 Financial Results:For its fiscal year 2011, Champions generated revenue of $6.9 million, an increase of $2 million or 41%, compared to fiscal year 2010.  

    Champions also reported a net loss of $3.8 million, or ($0.10) per share, compared to a net loss of $2.9 million, or ($0.09) per share, in the corresponding prior year.

    However, excluding stock based compensation* of $3.1 million, Champions recognized net loss of $0.7 million, or ($0.02) per share for 2011 compared to a net loss of $2.3 million excluding stock based compensation* of $0.6 million, or ($0.07) per share for 2010.

    Services RevenuesTotal revenues for fiscal 2011 were $6.9 million compared to $4.9 million for fiscal 2010, an increase of $2.0 million, or 41%.  Revenues from Personalized Oncology Solutions, ("POS"), were $3.4 million compared to $3.2 million in the prior year, an increase of $0.2 million, or 6%. Revenues from Translational Oncology Solutions, ("TOS"), previously referred to as Preclinical eValuation services, were $3.5 million for 2011 as the compared to $1.7 million in the prior year, an increase of $1.8 million, or 108%.

    Costs of POS for the fiscal year 2011 and 2010 were $1.6 million and $1.1 million, respectively, an increase of $0.5 million, or 44%.  The increase in costs for POS was due to the increased volume of POS business.  For the fiscal year 2011 and 2010, gross margins fo
    '/>"/>

    SOURCE Champions Oncology, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing
    2. Champions Biotechnology Changes Name to Champions Oncology
    3. Champions Announces Technology Collaboration Utilizing Champions Tumorgraft™ Technology Platform for Oncology Drug Development
    4. Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results
    5. Champions Biotechnology Reports Additions to its Management Team
    6. Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
    7. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
    8. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
    9. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
    10. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
    11. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... Virginia , September 2, 2015 ... der Gewinner des Wettbewerbs BeHEARD von 2015 bekanntgeben ... internationalen vom Rare Genomics Institute. Biovista ... von Medikamenten für die Behandlung anderer Krankheiten als ... Steven Laffoon und sein Team bei ...
    (Date:9/2/2015)... ... September 02, 2015 , ... The TS5-Q is ... commercial video content, to analysis of athletic performance. Producing high-resolution slow-motion video ... too quickly to process with the naked eye. , Slow motion sequences ...
    (Date:9/1/2015)... 2015 The American Brain Tumor Association (ABTA) ... Discovery Research Grant program. LOIs are due no later ... Discovery Grants are one-year, $50,000 grants that ... change current diagnostic or treatment paradigms for adults and ... research at its earliest stages, in the hopes that ...
    (Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... In her ... expertly transports the reader to a not-so-distant future faced with an Ebola pandemic that ... professional who overcomes personal tragedy to enter the world of counterterrorism, and who continues ...
    Breaking Biology Technology:Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3
    ... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced ... granted orphan drug designation for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, ... (LEMS). 3,4-DAP has previously received orphan drug designation ... Committee for Medicinal Products for Human Use of the ...
    ... , ... rapidly growing,orthobiologics company, was named Europe,s fastest growing,Biotech/Pharmaceutical/Medical Technology/Equipment company ... East and Africa). , This annual ... ApaTech has achieved a rate of 8,318% over this period. ...
    ... , , ... to market Oralair(R) in both adults and children,through a ... been marketed, was the reference Member state. , ... Belgium, Bulgaria, Cyprus, the,Czech Republic, Estonia, France, Germany, Greece, ...
    Cached Biology Technology:FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4ApaTech is Europe's Fastest Growing Lifescience Company 2ApaTech is Europe's Fastest Growing Lifescience Company 3ApaTech is Europe's Fastest Growing Lifescience Company 4STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3
    (Date:8/31/2015)... Growing need for data security coupled with ... drive India biometrics market   ... India Biometrics Market Forecast & Opportunities, 2020 ", biometrics market ... at a CAGR of over 35% during 2015 - 2020. ... use of biometric technology in the government sector. Ongoing government ...
    (Date:8/26/2015)... PUNE, India , August 26, 2015 ... (Two, Three, Four, and Five Factor), Application (Travel & ... and Geography - Global Forecast to 2020", published by ... 9.60 Billion by 2020, growing at a CAGR of ... 71 Tables and 82 F igures spread through ...
    (Date:8/24/2015)... VIEW, Calif. , Aug. 24, 2015  Based on ... Sullivan recognizes DERMALOG with the 2015 African Biometrics Company of ... and has achieved substantial commercial success in Africa ... Nigeria , where it has implemented one of the ... 23 banks as well as the Central Bank of ...
    Breaking Biology News(10 mins):India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6
    ... introduced ,Delicious, a new muscadine grape cultivar. ,Delicious, ripens ... fruit features exceptional taste and texture with an edible ... the potential for wine production. The name ,Delicious, was ... sampled the fruit., According to Dr. Dennis J. Gray, ...
    ... placed increasing demands on available water resources. In 2007, ... where the population approached two million people. The dual ... features frequent severe drought conditions has created an urgent ... meet resident and visitor demand., Las Vegas operates on ...
    ... vital component of good health. Like plants that thrive in ... case for the production of vitamin D. In the past ... sun exposure. From fear of the potential dangers of UV ... work and recreational environments centered on virtual reality, we are ...
    Cached Biology News:Keeping golf courses green when fresh water is limited 2Keeping golf courses green when fresh water is limited 3The sunlight solution for better health 2The sunlight solution for better health 3
    ... The Bio-Stack is compatible with ... systems. Speed, ease of use and ... routine microplate process. When used with ... reagent dispenser, the Bio-Stacks small footprint ...
    ... use of small interfering RNA (siRNA) molecules ... interference,(RNAi) pathway have generated tremendous interest in ... for experimental use can be,synthesized in vitro, ... into the target cells in vitro or ...
    ... S&S Custom Array Service enables scientists who have ... to have FAST Slides printed with proteins from ... Processing of the arrays is performed by the ... S&S to discuss your needs with an expert ...
    ... demands of the routine trace metal analytical ... robust and simple to use instrumentation. The ... most challenging sample matrices found in the ... the toughest analytical challenges found in the ...
    Biology Products: